



4th IBD ACADEMY



ASOCIJACIJA
GASTROENTEROLOGA
I HEPATOLOGA
U BOSNI I HERCEGOVINI

**25-26
SEPTEMBER 2026**

Hotel Mellain, Tuzla

freestyle
marketing agency



www.kongres.ba

Dear Colleagues,

It is our great pleasure to invite you to the 4th IBD Academy 2026, which will be held on September 25–26, 2026, in Tuzla, at Hotel Mellain.

Inflammatory bowel diseases (IBD) represent one of the most dynamic fields in modern gastroenterology. The development of new therapeutic options, the growing importance of personalized medicine, and the need for a multidisciplinary approach continuously present clinicians with new questions and challenges.

This year's IBD Academy has been designed as an interactive platform for the exchange of experience and practical knowledge. The program will include:

- the latest scientific advances in the field of IBD,
- multidisciplinary discussions of complex clinical cases,
- debates on controversial topics in treatment,
- practical sessions focused on everyday clinical decision-making.

Special attention will be given to issues we encounter daily in clinical practice:

- whether our patients are sometimes overtreated or undertreated,
- when the right time is for surgical intervention,
- how to manage therapy-related adverse effects,
- how to optimize treatment in the era of new biologics and small-molecule therapies,
- and how to improve the quality of life of our patients.

We believe that the IBD Academy 2026 will provide an excellent opportunity to acquire new knowledge, exchange experiences, and strengthen professional collaboration among specialists involved in the treatment of patients with ulcerative colitis and Crohn's disease.

We look forward to welcoming you and sharing this valuable experience together.

Sincerely,



Prof. Dr. Mirela Bašić Denjagić
President of the Organizing Committee
4th IBD Academy 2026

ORGANIZERS

Association of Gastroenterologists and Hepatologists of Bosnia and Herzegovina
Department of Gastroenterology and Hepatology, Clinic of Internal Medicine, University Clinical
Centre Tuzla

PRESIDENT

Prof. dr Mirela Bašić Denjagić

ORGANIZING COMMITTEE

Prof. dr Predrag Jovanović
Prof. dr Ervin Alibegović
dr Majda Mehmedović
dr Selma Hodžić

SCIENTIFIC COMMITTEE

Prof. dr Ervin Alibegović
Prof. dr Milenko Bevanda
Prof. dr Rusmir Mesihović
Prof. dr Azra Husić
Prof. dr Nenad Vanis
Prof. dr Stevan Trbojević
Prof. dr Predrag Jovanović
Doc. dr Nadža Zubčević
Prof. dr Emil Babić
Doc. dr Amila Mehmedović
mr med. sci. Aida Pilav
dr Renata Tamburić
dr Tatjana Barać
dr Selma Hodžić

TECHNICAL ORGANIZER

FREESTYLE d.o.o. Tuzla
ul. Maršala Tita 109
75 000 Tuzla BiH
tel: +387 35 310 510 +387 35 310 511
e mail: info@kongres.ba
web: www.kongres.ba

VENUE

Hotel Mellain, Tuzla
ul. Aleja Alije Izetbegovića br. 3
75 000 Tuzla
tel: 035 365-500
web: www.mellainhotel.ba

REGISTRATION FEES

BAM 250.00 – Specialists
BAM 200.00 – Residents (Specialty Trainees)
BAM 150.00 – Nurses and Medical Technicians

** A 17% VAT will be added to the above fees.*

REGISTRATION

Participants are kindly requested to complete the online registration form, which will be available on www.kongres.ba, or contact the organizers via e-mail at: info@kongres.ba registracija@kongres.ba

ACCOMMODATION

HOTEL MELLAIN
ul. Aleja Alije Izetbegovića 3
75 000 Tuzla

HOTEL GRAND TUZLA
ul. ZAVNOBIH-a 13
75 000 Tuzla

HOTEL VERTIGOS
ul. Kulina Bana 2
75 000 Tuzla

FRIDAY, SEPTEMBER 25

09:00–09:30 Registration

09:30 Opening of the Scientific Program

09:30–17:00 Scientific Program (Lectures, Panel Discussions, and Other Scientific Sessions)

Four 15-minute satellite symposia will be held during the program.

The detailed schedule will be published in the final program.

SATURDAY, SEPTEMBER 26

09:00–15:00 Scientific Program and Parallel Nursing Session

One 30-minute satellite symposium will be held during the program.

The detailed schedule will be published in the final program.

SCIENTIFIC PROGRAM TOPICS

State-of-the-Art Lectures

- Artificial Intelligence in IBD: Can AI improve disease diagnosis and assessment of disease activity?
- The Appendix and Mesenteric Fat in IBD: Friend or foe?
- Why Do Patients with IBD Experience Disease Flares?
- The Risks of Undertreatment and Overtreatment in IBD: Are we achieving the right balance?
- What Is the Cost of IBD Complications? A practical perspective on pharmacoeconomics

Multidisciplinary Clinical Discussion

Surgeon • Oncologist • Pathologist • Gastroenterologist

Postoperative Crohn's Disease

- Postoperative remission in Crohn's disease – are we treating these patients too aggressively?
- Postoperative relapse of Crohn's disease – are we undertreating these patients? Lessons learned from the management of chronic abscesses

Ulcerative Colitis and Surgical Dilemmas

- Acute severe ulcerative colitis and colectomy – when is the right time for surgery?

Dysplasia and Cancer in IBD

- Carcinoma in situ in IBD – to operate or not?
 - Adenocarcinoma arising from a fistula tract – diagnostic and therapeutic challenges
-

Multidisciplinary Clinical Discussion

Psychiatrist • Clinical Pharmacologist • Gastroenterologist • Nephrologist

- Ulcerative colitis, renal insufficiency, and sexual dysfunction – a challenging clinical case
 - Microscopic colitis – why is the diagnosis sometimes so difficult to establish?
 - When patients refuse treatment – communication strategies in the era of social media and influencers
-

Tandem Lectures

What Is the Most Effective Therapy for Acute Severe Ulcerative Colitis?

- Infliximab or cyclosporine?
- Upadacitinib or tofacitinib?

What Is the Optimal First-Line Therapeutic Strategy for Biologic-Naïve Patients with Ileocecal Disease?

- Biologic therapy or early surgical intervention?

Fertility and Sexual Health in IBD: Who Faces Greater Challenges?

- Men or women?

Mesalazine in the Prevention of Colorectal Cancer

- Fact or myth?
-

Optimizing IBD Treatment

Optimizing Advanced Therapies in Everyday Clinical Practice

- How can we make the right decision at the right time?

Vedolizumab in Different Clinical Scenarios

- Early Crohn's disease
- Postoperative relapse of Crohn's disease
- Fistulizing Crohn's disease
- Pediatric population

Positioning IL-23 Inhibitors in the Therapeutic Algorithm

- Crohn's disease and ulcerative colitis
- Early use versus use in previously treated patients
- Fistulizing disease
- Switching from anti-TNF therapy

Obesity and IBD

- Does obesity affect treatment outcomes?
- Should we approach these patients differently?

IBS-like Symptoms and Chronic Pain in Patients with IBD

- How can we recognize and manage them?
-

Practical Sessions

- My patient has a rash – what next?
 - My patient has elevated liver enzymes – what next?
 - My patient has joint pain – what next?
-